Eric Devroe - 14 Nov 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Chief Operating Officer
Issuer ticker: ACRV
Reported as of: 14 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Nov 2022, 18:18:09 UTC
Prior SEC filing: 09 Nov 2022
Next SEC filing: 06 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact

Key filing fact

Eric Devroe filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 16 Nov 2022.

Key facts

This page summarizes Eric Devroe's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Nov 2022, 18:18.

Change

Previous filing in this sequence was filed on 09 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRV transaction

Common Stock

Award

Transaction value: $0
Shares: +33,383
Change %: +165%
Price: $0.000000
Shares after: 53,658
Date: 14 Nov 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +100,150
Change %
Price: $0.000000
Shares after: 100,150
Date: 14 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,150
Exercise price: $12.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Footnote F2

Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.